Zenas BioPharma Surges 6.9% on Breakthrough Trial Results – Is This the Start of a Biotech Renaissance?

Summary
• Zenas BioPharma (ZBIO) surges 6.9% intraday, hitting a 52-week high of $35.98
• Positive Phase 2 MoonStone trial results for obexelimab in Relapsing Multiple Sclerosis drive momentum
• Analysts upgrade targets, with six 'Buy' ratings and an average price target of $44.33

Zenas BioPharma’s stock has erupted to a 52-week high amid groundbreaking clinical data and bullish analyst sentiment. The stock’s 6.9% intraday surge reflects investor optimism over its autoimmune disease pipeline and strategic positioning in a sector marked by innovation. With insider buying and institutional inflows, the biotech’s momentum suggests a pivotal shift in market perception.

Phase 2 MoonStone Trial Ignites Clinical Optimism
Zenas BioPharma’s explosive move stems from its positive Phase 2 MoonStone trial results for obexelimab in Relapsing Multiple Sclerosis (RMS). The data, announced in late October 2025, demonstrated robust efficacy in targeting B cells, a critical pathway for autoimmune diseases. This milestone not only validates the company’s therapeutic approach but also accelerates regulatory timelines, drawing attention to upcoming INDIGO and SunStone trial results. Analysts from Jefferies and Wedbush have raised price targets to $52 and $45, respectively, while insider purchases of $17.6M underscore conviction in the stock’s long-term potential.

Biotech Sector Gains Momentum as Zenas Leads Rally
The biotech sector has seen renewed vigor, with Amgen (AMGN) surging 3.5% and institutional investors pouring into Zenas BioPharma. While Amgen’s rally reflects broader market confidence in large-cap biotech, Zenas’s performance highlights speculative enthusiasm for early-stage innovators. The sector’s focus on autoimmune and rare disease therapies aligns with Zenas’s pipeline, positioning it as a high-growth contender amid a $4.26 trillion biotech market projected to expand through 2033.

Options and ETFs to Capitalize on Zenas’s Bullish Momentum
• MACD: 2.56 (above signal line 2.31), RSI: 63.08 (neutral), 200D MA: $13.85 (far below current price)
• Bollinger Bands: Price at $34.71, above middle band ($28.40), near upper band ($34.97)
• Support/Resistance: 30D support at $32.33, 200D support at $9.69

Zenas BioPharma’s technicals suggest a continuation of its bullish trend, with key resistance at $35.98 (52-week high) and support at $32.33. The stock’s 6.9% intraday gain and elevated RSI indicate strong short-term momentum, while the MACD histogram’s positive divergence signals sustained buying pressure. For leveraged exposure, consider boldETFs if available, though none are listed here. Instead, focus on options with high leverage and implied volatility.

Top Options Picks:
• ZBIO20251121C35
- Strike: $35, Expiration: 2025-11-21, IV: 69.07%, Delta: 0.501, Theta: -0.135, Gamma: 0.0958, Turnover: $4,360
- IV: High volatility suggests strong price swings; Delta: 50% implies balanced directional exposure; Gamma: High sensitivity to price movement enhances leverage.
- This call option offers a 22.4% leverage ratio and high gamma, ideal for capitalizing on near-term volatility. A 5% upside to $36.45 would yield a payoff of $1.45 per contract, translating to a 4.2% return on the $35 strike.
• ZBIO20260515C35
- Strike: $35, Expiration: 2026-05-15, IV: 68.61%, Delta: 0.607, Theta: -0.0207, Gamma: 0.0226, Turnover: $0
- IV: Slightly lower than the November contract but still robust; Delta: 60.7% indicates stronger directional bias; Gamma: Moderate sensitivity for controlled leverage.
- This longer-dated option balances time decay (theta) with directional exposure. A 5% upside would yield a $1.45 payoff, with the May 2026 expiration allowing for extended holding periods as the INDIGO trial progresses.

Aggressive bulls should prioritize ZBIO20251121C35 for short-term gains, while ZBIO20260515C35 suits those betting on sustained momentum through 2026. Both contracts align with Zenas’s clinical catalysts and sector tailwinds.

Backtest Zenas BioPharma Stock Performance
I attempted to retrieve daily price data for the ticker “ZBIO.O” from 2022-01-01 to today so that I could identify every ≥ 7 % intraday surge, but the data source returned an empty result set. This usually means one of the following:1. The ticker symbol (ZBIO.O) is not recognized by the data provider or has not yet been listed for the full period requested. 2. The symbol trades on an exchange that isn’t supported by the current data connector. 3. The company might be privately held or recently listed with limited historical data.To proceed, could you please help me confirm one of these options?• Verify whether ZBIO.O is the correct, actively traded ticker and, if so, since which date it has had regular market data. • If the symbol is correct but has a different start date than 2022-01-01, please provide the actual listing date (or any earliest date you’re interested in). • If you have specific dates when ZBIO experienced intraday surges of ≥ 7 %, you can provide them directly, and I can run the event-driven back-test using those dates. Once we have valid price data or a confirmed list of surge dates, I can immediately set up and run the back-test for you.

Zenas BioPharma’s Breakout: A Catalyst-Driven Opportunity
Zenas BioPharma’s 6.9% surge is a testament to the power of clinical milestones in biotech. With obexelimab’s Phase 2 success and a $44.33 average analyst target, the stock is primed for further gains if INDIGO and SunStone trials deliver. Investors should monitor the $35.98 52-week high as a critical resistance level and watch Amgen’s 3.5% rally for sector-wide cues. For those seeking leverage, the ZBIO20251121C35 option offers a high-gamma, high-leverage play on near-term volatility. Act now: Buy ZBIO20251121C35 if $35.98 is breached, or hold for the May 2026 option if the stock consolidates above $32.33.